Result of Annual General Meeting 2022 (1370371)

Arix Bioscience PLC (ARIX) Result of Annual General Meeting 2022 07-Jun-2022 / 16:44 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Result of Annual General Meeting 2022

LONDON, 7 June 2022: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's website.

                                                                             VOTES           TOTAL      % of   VOTES 
No            RESOLUTION                                   VOTES FOR  %      AGAINST   %     VOTES      ISC    WITHHELD 
                                                                                                        VOTED 
              To receive the Directors' Report and the 
1             accounts of the Company for the year ended   63,669,622 99.99% 5,609     0.01% 63,675,231 49.29% 10,853 
              31 December 2021 
2             To approve the Directors' Remuneration       63,589,770 99.90% 65,188    0.10% 63,654,958 49.28% 31,126 
              Policy 
3             To approve the Directors' Remuneration       60,232,861 94.62% 3,422,747 5.38% 63,655,608 49.28% 30,476 
              Report 
4             To re-elect Peregrine Moncreiffe as a        60,068,424 94.35% 3,599,164 5.65% 63,667,588 49.29% 18,496 
              Director 
5             To re-elect Maureen O'Connell as a Director  59,600,160 93.61% 4,068,028 6.39% 63,668,188 49.29% 17,896 
6             To re-elect Isaac Kohlberg as a Director     63,450,417 99.66% 217,771   0.34% 63,668,188 49.29% 17,896 
7             To re-elect Robert Lyne as a Director        63,451,455 99.66% 216,733   0.34% 63,668,188 49.29% 17,896 
8             To elect Sir Michael Bunbury as a Director   60,231,844 94.60% 3,436,344 5.40% 63,668,188 49.29% 17,896 
9             To appoint BDO LLP as auditors of the        63,659,891 99.98% 12,947    0.02% 63,672,838 49.29% 13,246 
              Company 
              To authorise the Audit and Risk Committee of 
10            the Company to fix the auditor's             63,667,766 99.99% 4,772     0.01% 63,672,538 49.29% 13,546 
              remuneration 
11            To authorise the Directors to allot shares   63,632,590 99.94% 40,130    0.06% 63,672,720 49.29% 13,364 
12            Authority to disapply statutory pre- emption 58,648,467 92.11% 5,021,253 7.89% 63,669,720 49.29% 16,364 
              rights 
13            Additional authority to disapply statutory   58,653,953 92.12% 5,015,767 7.88% 63,669,720 49.29% 16,364 
              pre- emption rights 
14            To authorise the Company to purchase its own 63,648,630 99.96% 22,560    0.04% 63,671,190 49.29% 14,894 
              shares 
              Authority to call a general meeting, other 
15            than an annual general meeting, on not less  63,666,745 99.99% 8,786     0.01% 63,675,531 49.29% 10,553 
              than 14 clear days' notice 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2022, which is available on Arix investor relations website.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

[phone]

[e-mail]

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

-----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  RAG 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   166768 
EQS News ID:    1370371 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1370371&application_name=news

(END) Dow Jones Newswires

June 07, 2022 11:44 ET (15:44 GMT)